Press Releases

Media Contact: Michelle Kirkwood, Vice President, Strategic Communications and Public Relations, press@diabetes.org

The most recent press releases from the American Diabetes Association:

June 25, 2018
Diabetes Emergency Relief Coalition Wins Top Association Honor
The Diabetes Emergency Relief Coalition (Coalition), composed of leading diabetes care and research organizations, will receive the American Society of Association Executives (ASAE) 2018 Summit Power of A Award for helping to provide critical diabetes supplies to regions impacted by Hurricanes Harvey, Irma and Maria, the Coalition announced today.

June 25, 2018
Metformin Alone or Combined with Insulin Does Not Improve or Preserve Beta-Cell Function in Youth with Impaired Glucose Tolerance or Newly Diagnosed Type 2 Diabetes
According to recent research, the insulin resistance and pancreatic beta-cell (β-cell) dysfunction associated with type 2 diabetes (T2D) was unresponsive to treatment with metformin alone or metformin combined with insulin glargine in youth with impaired glucose tolerance (IGT), which is an element of prediabetes, or early T2D.

June 25, 2018
Carol and Mark A. Atkinson, PhD, Receive American Diabetes Association’s Humanitarian Award
Carol and Mark A. Atkinson, PhD, of Insulin for Life USA, are the recipients of the American Diabetes Association’s® (ADA’s) Humanitarian Award. This one-time award honors their outstanding leadership and humanitarian efforts to support the diabetes community for the Diabetes Emergency Relief Coalition in 2017.

June 25, 2018
Expanded Access to Prevention Programs and Acknowledging Increased Risk of Depression Among People with Diabetes Can Reduce Complications and Prevalence, and Improve Outcomes and Quality of Life
Diabetes is a unique and complex disease affecting more than 30 million Americans, and the individual living with diabetes is solely responsible for daily diabetes management.

June 25, 2018
Type 2 Diabetes Risk in Asian Indian Immigrants in U.S. Impacted by Adopted Lifestyle Habits
New research shows that Asian Indian immigrants in the U.S. are at increased risk for chronic diseases including type 2 diabetes (T2D) and cardiovascular disease (CVD). Adopting American lifestyle behaviors may specifically affect HbA1c levels and high-density lipoproteins (HDL) cholesterol levels in this group, according to the study, “Mediating Role of Acculturation and Lifestyle Behaviors on Cardiometabolic Risks among Asian Indians in the United States,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

June 24, 2018
Intense Multifactorial Treatment for Type 2 Diabetes Shown to be Cost Effective
When patients with type 2 diabetes (T2D) receive intensified, multifactorial treatment combining lifestyle modification and pharmacological therapy for modifiable risk factors, there is no significant increase in medical costs, compared to patients who receive conventional, multifactorial treatment, according to the study, “A Cost Analysis of Intensified vs. Conventional Multifactorial Therapy of Patients with Type 2 Diabetes—The Steno 2 Study,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

June 24, 2018
Adding Liraglutide to Insulin Regimen for People with Type 1 Diabetes Improved Glycemic Control
Adults with type 1 diabetes (T1D) who take a daily dose of liraglutide demonstrated improvements in HbA1c levels, weekly average blood glucose levels and increased weight loss, according to the study, “Liraglutide as an Additional Treatment to Insulin in Patients with Type 1 Diabetes Mellitus—A 52-Week Randomized Double-Blinded Placebo-Controlled Clinical Trial,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

June 24, 2018
Alirocumab and Statins Highly Effective in People with Diabetes with Acute Coronary Syndrome
People with diabetes who have experienced recent acute coronary syndrome (ACS) and take a combination of alirocumab and statins may reduce their risk of future cardiac events by more than double that of people on the same medication regimen who have similar cardiac histories, but have prediabetes or normal blood glucose levels, according to the study, “Alirocumab and Cardiovascular Outcomes in Patients with Acute Coronary Syndrome (ACS) and Diabetes—Prespecified Analyses of ODYSSEY OUTCOMES,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

June 24, 2018
Real World Study Suggests Canagliflozin Does Not Increase Risk of Below- Knee Amputation in People with Type 2 Diabetes
Canagliflozin does not increase the risk of amputation for the general type 2 diabetes (T2D) population or in patients with established cardiovascular disease, but does reduce a patient’s risk of hospitalization for heart failure, according to the study, “Canagliflozin (CANA) vs. Other Antihyperglycemic Agents on the Risk of Below-Knee Amputation (BKA) for Patients with T2DM—A Real-World Analysis of >700,000 U.S. Patients,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center Convention Center.

June 24, 2018
Dapagliflozin as Adjunct Therapy to Insulin for People with Type 1 Diabetes May Improve Glycemic Control
Adding the selective SGLT2 inhibitor dapagliflozin to intensive insulin therapy in adults with type 1 diabetes (T1D) who had sub-optimal glycemic control reduced blood glucose levels, aided in weight loss and led to a reduction in insulin doses, yet also correlated with a slight increase in diabetic ketoacidosis risk compared to placebo, according to the study “Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes—DEPICT-2 Study,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center Convention Center.

June 24, 2018
Sotagliflozin in Conjunction with Insulin for Type 1 Diabetes Reduces Average Blood Glucose Levels
People with type 1 diabetes (T1D) who take 200 mg or 400 mg of sotagliflozin in addition to optimized insulin therapy have statistically lower HbA1c levels and weight, as well as low incidence of severe hypoglycemia after a year of treatment, compared to those who take a placebo with optimized insulin, according to the study, “Fifty-Two-Week Efficacy and Safety of Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes (inTandem1),” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

June 23, 2018
Omnipod® Hybrid Closed-Loop Insulin Delivery System Significantly Improves Glycemic Control in Adults with Type 1 Diabetes
Adults with type 1 diabetes using the Omnipod hybrid closed-loop system (the HorizonTM Automated Glucose Control System) were studied in a supervised outpatient hotel setting with unrestricted meals and moderate-intensity exercise and experienced significantly less hypoglycemia, more time in the target glucose range and better overnight glycemic control compared to their usual care, according to the study, “Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults with Type 1 Diabetes over Five Days Under Free-Living Conditions,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center Convention Center.

June 23, 2018
Dual-Hormone, Artificial Pancreas with Insulin and Pramlintide Significantly Improves Glucose Levels, Compared to Insulin-Only Artificial Pancreas
A dual-hormone, artificial pancreas delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an insulin-only, first-generation artificial pancreas, according to the study, “Insulin-plus-Pramlintide Artificial Pancreas in Type 1 Diabetes—Randomized Controlled Trial,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center Convention Center.

June 23, 2018
Fully Implantable, Continuous Glucose Monitoring Sensor Provided Accuracy for Six Months in Adolescents and Adults with Type 1 Diabetes
When adolescents and adults with type 1 diabetes (T1D) used a new continuous glucose monitoring (CGM) device containing a sensor that can remain implanted in the arm for up to 180 days, the system provided accurate glucose measurement with no major side effects, according to the study, “First Assessment of the Performance of an Implantable CGM System through 180 Days in a Primarily Adolescent Population with Type 1 Diabetes,” presented today at the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at the Orange County Convention Center.

June 23, 2018
Diabeloop Insulin Delivery System May Significantly Improve Glycemic Control for People with Type 1 Diabetes
New research finds that people with type 1 diabetes (T1D) who used the Diabeloop DBLG1 therapeutic, closed-loop insulin delivery system in a home setting experienced a greater percentage of time in the target blood glucose range and fewer hypoglycemic events compared to patients who used an open-loop system, consisting of their regular pump and sensor.

June 22, 2018
Identifying and Reducing Gender Gaps in Diabetes—Care, Research and the Health Care Profession
A distinctive panel of female leaders in the field of diabetes care and research are convening for several sessions during the American Diabetes Association’s® (ADA’s) 78th Scientific Sessions® at Orlando’s Orange County Convention Center to discuss and examine gender issues, gaps, and biases as they relate to the field of diabetes care, research and heath care careers.

June 15, 2018
Leading health organizations collaborate with industry on new initiative to combat growing diabetes and cardiovascular disease threat
The American Heart Association (AHA) and the American Diabetes Association (ADA) today announced the start of a new multi-year collaborative initiative supported by founding sponsors Boehringer Ingelheim, Eli Lilly and Company (Lilly), and Novo Nordisk.

June 14, 2018
Rita Rastogi Kalyani, MD, MHS, to Receive American Diabetes Association’s 2018 Vivian Fonseca and Nagendran Family Diabetes Research Award
Rita Rastogi Kalyani, MD, MHS, has been selected to receive the American Diabetes Association’s (ADA’s) 2018 Vivian Fonseca and Nagendran Family Diabetes Research Award.

June 14, 2018
Patient Groups: Uphold Health Care Law As Congress Intended
Patient groups representing millions of Americans with pre-existing conditions filed an amicus curiae or friend of the court brief today in the U.S. District Court case, Texas v. United States, citing the devastating impact patients would face should the court side with plaintiffs and move to invalidate the Affordable Care Act (ACA).

June 12, 2018
Alessandro Doria, MD, PhD, MPH, Receives the American Diabetes Association’s 2018 Edwin Bierman Award
Alessandro Doria, MD, PhD, MPH, has been selected to receive the American Diabetes Association’s® (ADA’s) 2018 Edwin Bierman Award.

  • Last Reviewed: November 18, 2013
  • Last Edited: April 11, 2018